These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15614708)

  • 1. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
    Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
    Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in viral load in people with virological failure who remain on the same HAART regimen.
    Cozzi-Lepri A; Phillips AN; Miller V; Katlama C; Ledergerber B; Vella S; Weber J; Bruun JN; Kirk O; Clotet B; Lundgrens JD
    Antivir Ther; 2003 Apr; 8(2):127-36. PubMed ID: 12741625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
    Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
    J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study.
    DeHovitz JA; Kovacs A; Feldman JG; Anastos K; Young M; Cohen M; Gange SJ; Melnick S; Greenblatt RM
    J Infect Dis; 2000 Nov; 182(5):1527-30. PubMed ID: 11010840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
    Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
    J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.
    Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
    Clin Infect Dis; 2002 Dec; 35(12):1541-8. PubMed ID: 12471575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of highly active antiretroviral therapy (HAART) in a cohort of patients with HIV infection in Mexico].
    Jáuregui Camargo L; Ruiz-Palacios G; Guerrero Almeida L; Niño Oberto S; Peasey A; Sierra Madero J
    Rev Invest Clin; 2003; 55(1):10-7. PubMed ID: 12708158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients.
    Rodriguez B; Woolley I; Lederman MM; Zdunek D; Hess G; Valdez H
    J Infect Dis; 2003 Feb; 187(3):504-7. PubMed ID: 12552436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of pregnancy to the use of highly active antiretroviral therapy.
    Minkoff H; Ahdieh L; Watts H; Greenblatt RM; Schmidt J; Schneider M; Stek A
    Am J Obstet Gynecol; 2001 May; 184(6):1221-7. PubMed ID: 11349192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy.
    Ragni MV; Bontempo FA
    J Infect Dis; 1999 Dec; 180(6):2027-9. PubMed ID: 10558963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy.
    Dufour V; Wislez M; Bergot E; Mayaud C; Cadranel J
    Clin Infect Dis; 2003 May; 36(10):e127-30. PubMed ID: 12746792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Wanke CA; Silva M; Knox TA; Forrester J; Speigelman D; Gorbach SL
    Clin Infect Dis; 2000 Sep; 31(3):803-5. PubMed ID: 11017833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?
    Giordano TP; Wright JA; Hasan MQ; White AC; Graviss EA; Visnegarwala F
    Clin Infect Dis; 2003 Aug; 37(3):433-7. PubMed ID: 12884169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline.
    Nikolic-Djokic D; Essajee S; Rigaud M; Kaul A; Chandwani S; Hoover W; Lawrence R; Pollack H; Sitnitskaya Y; Hagmann S; Jean-Philippe P; Chen SH; Radding J; Krasinski K; Borkowsky W
    J Infect Dis; 2002 Feb; 185(3):290-8. PubMed ID: 11807710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy.
    Batterham MJ; Garsia R; Greenop P
    Int J STD AIDS; 2002 Nov; 13(11):744-7. PubMed ID: 12437893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication.
    Wendel KA; McArthur JC
    Clin Infect Dis; 2003 Oct; 37(8):1107-11. PubMed ID: 14523776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy.
    Saulsbury F
    Clin Infect Dis; 2001 Feb; 32(3):464-8. PubMed ID: 11170955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men.
    Roubenoff R; Grinspoon S; Skolnik PR; Tchetgen E; Abad L; Spiegelman D; Knox T; Gorbach S
    Am J Physiol Endocrinol Metab; 2002 Jul; 283(1):E138-45. PubMed ID: 12067854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.
    Ellis RJ; Childers ME; Zimmerman JD; Frost SD; Deutsch R; McCutchan JA;
    J Infect Dis; 2003 Jun; 187(11):1818-21. PubMed ID: 12751041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.
    Banic S; Koren S; Tomazic J; Vidmar L; Ihan A; Poljak M; Avsic-Zupanc A
    Acta Virol; 2001 Feb; 45(1):39-44. PubMed ID: 11394576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.